daunorubicin
Selected indexed studies
- Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia. (Drugs, 2018) [PMID:30511323]
- Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes. (Ann Pharmacother, 2018) [PMID:29532662]
- Production of daunorubicin. (Adv Biotechnol Processes, 1984) [PMID:6399841]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia. (2018) pubmed
- Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes. (2018) pubmed
- Production of daunorubicin. (1984) pubmed
- Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. (1984) pubmed
- Daunorubicin and its hydroxy metabolite in cardiomyocytes: insights into cellular kinetics, toxicity, DNA damage, and dexrazoxane-induced cardioprotection. (2025) pubmed
- Conjugating Daunorubicin and Doxorubicin to GTP by Formaldehyde to Overcome Drug Resistance. (2024) pubmed
- Letter: Daunorubicin cardiotoxicity. (1976) pubmed
- Regulation of daunorubicin biosynthesis in Streptomyces peucetius - feed forward and feedback transcriptional control. (2013) pubmed
- CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. (2019) pubmed
- High-dose versus standard-dose daunorubicin in induction therapy for young patients with de novo acute myeloid leukaemia: a meta-analysis of randomised trials. (2016) pubmed